DAMP—Induced Allograft and Tumor Rejection: The Circle Is Closing

American Journal of Transplantation

Volumn 16, Issue 12, 2016, Pages 3322-3337

  Land, W G ^a,b   Agostinis, P ^c   Gasser, S ^d   Garg, A D ^c   Linkermann, A ^e,f,g   Abendroth, Dietmar K ^h   Adam, Dieter ^h   Anders, Hans Joachim ^h   Arbogast, Helmut P ^h   Baan, Carla ^h   Bahram, Seiamak ^h   Becker, Jan Ulrich ^h   Bonventre, Joseph V ^h   Bräsen, Jan Hinrich ^h   Cantley, Lloyd G ^h   Chandraker, Anil ^h   Daar, Abdallah ^h   Daehn, Ilse ^h   Dragun, Dushka ^h   Dubernard, Jean Michel ^h   Falk, Christine S ^h   Georgel, Philippe ^h   Green, Douglas R ^h   Grinyo, Josep ^h   Haberal, Mehmet ^h   Haller, Hermann ^h   Halloran, Philip F ^h   Heller, Jan Ole ^h   Hertig, Alexandre ^h   Hilbrands, Luuk ^h   Huber, Tobias B ^h   Janssen, Ottmar ^h   Jevnikar, Anthony M ^h   Kirk, Allan D ^h   Kitsis, Richard N ^h   Kupiec Weglinski, Jerzy ^h   Kunzendorf, Ulrich ^h   Kroemer, Guido ^h   Kurts, Christian ^h   Ma, Daqing ^h   Maltzman, Jonathan ^h   Margreiter, Raimund ^h   Massard, Gilbert ^h   Messmer, Konrad ^h   Morris, Randall ^h   Murphy, James ^h   Nashan, Björn ^h   Oberst, Andrew ^h   Ortiz, Alberto ^h   Overholtzer, Mike ^h   Ponticelli, Claudio ^h   Rothstein, David M ^h   Sanz, Ana B ^h   Schiffer, Mario ^h   Schröppel, Bernd ^h   Schulte, Kevin ^h   Seong, S Y ^h   Sibilia, Jean ^h   Siedlecki, Andrew M ^h   Sollinger, Hans Werner ^h   Strom, Terry B ^h   Stockwell, Brent R ^h   Szabó, Attila J ^h   Tonnus, Wulf ^h   Trivedi, H L ^h   Tullius, Stephan G ^h   Turka, Laurence A ^h   Turnquist, Heth ^h   Vandenabeele, Peter ^h   Vanden Berghe, Tom ^h   Walczak, Henning ^h   Weinberg, Joel M ^h   Wolf, Philippe ^h   Zierleyn, Adrian ^h   more..

^a German Academy of Transplantation Medicine   (Germany)

^b UNIVERSITÉ DE STRASBOURG   (France)

^c LABORATORY OF MOLECULAR AND CELLULAR SIGNALING   (Belgium)

^d NATIONAL UNIVERSITY OF SINGAPORE   (Singapore)

^e UNIVERSITY HOSPITAL CARL GUSTAV CARUS   (Germany)

^f Inflammation at Interfaces   (Germany)

^g UNIVERSITY OF KIEL   (Germany)

^h NONE

Author keywords

basic (laboratory) research science; cancer malignancy neoplasia; cell death; immune regulation; immunobiology; organ transplantation in general; rejection; rejection: antibody mediated (ABMR); translational research science

Indexed keywords

ADENOSINE TRIPHOSPHATE; BIOLOGICAL FACTOR; CALRETICULIN; COMPLEMENT MEMBRANE ATTACK COMPLEX; CYTOKINE; DAMAGE ASSOCIATED MOLECULAR PATTERN; DNA; HEAT SHOCK PROTEIN 70; HEAT SHOCK PROTEIN 90; HIGH MOBILITY GROUP B1 PROTEIN; HLA A ANTIGEN; HLA B ANTIGEN; INTERFERON; T LYMPHOCYTE RECEPTOR; TOLL LIKE RECEPTOR; TOLL LIKE RECEPTOR 3; UNCLASSIFIED DRUG;

ACUTE GRAFT REJECTION; ALLOIMMUNITY; CANCER CELL; CANCER IMMUNOTHERAPY; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CELL DEATH; DENDRITIC CELL; ENDOPLASMIC RETICULUM STRESS; GRAFT REJECTION; HUMAN; IMMUNE RESPONSE; IMMUNOSURVEILLANCE; INFLAMMATION; MEDIATOR RELEASE; MEDICAL RESEARCH; NONHUMAN; OXIDATIVE STRESS; PRIORITY JOURNAL; REPERFUSION INJURY; REVIEW; TH1 CELL; TUMOR NECROSIS; TUMOR REJECTION; ALLOGRAFT; ANIMAL; IMMUNOLOGY; NECROSIS; NEOPLASM; PATHOLOGY; PATHOPHYSIOLOGY;

ALLOGRAFTS; ANIMALS; GRAFT REJECTION; HUMANS; INFLAMMATION; NECROSIS; NEOPLASMS; REPERFUSION INJURY;

EID: 84988336228     PISSN: 16006135     EISSN: 16006143     Source Type: Journal    
DOI: 10.1111/ajt.14012     Document Type: Review

References (159)

1. Land W, Schneeberger H, Schleibner S, et al. The beneficial effect of human recombinant superoxide dismutase on acute and chronic rejection events in recipients of cadaveric renal transplants. Transplantation 1994; 57: 211–217.
2. Matzinger P. Tolerance, danger, and the extended family. Annu Rev Immunol 1994; 12: 991–1045.
3. Heil M, Land WG. Danger signals—Damaged-self recognition across the tree of life. Front Plant Sci 2014; 5: 578.
4. Land W. Allograft injury mediated by reactive oxygen species: From conserved proteins of Drosophila to acute and chronic rejection of human transplants—Part III: Interaction of (oxidative) stress-induced heat shock proteins with Toll-like receptor-bearing cells of innate immunity and its consequences for the development of acute and chronic allograft rejection. Transplant Rev 2003; 17: 67–86.
5. Seong SY, Matzinger P. Hydrophobicity: An ancient damage-associated molecular pattern that initiates innate immune responses. Nat Rev Immunol 2004; 4: 469–478.
6. Land WG, Agostinis P, Gasser S, Garg AD, Linkermann A. Transplantation and damage associated molecular patterns (DAMPs). Am J Transplant. In press 2016.
7. Omenetti S, Pizarro TT. The Treg/Th17 Axis: A dynamic balance regulated by the gut microbiome. Front Immunol 2015; 6: 639.
8. Tanoue T, Atarashi K, Honda K. Development and maintenance of intestinal regulatory T cells. Nat Rev Immunol 2016; 16: 295–309.
9. Ruocco MG, Chaouat G, Florez L, Bensussan A, Klatzmann D. Regulatory T-cells in pregnancy: Historical perspective, state of the art, and burning questions. Front Immunol 2014; 5: 389.
10. Figueiredo AS, Schumacher A. The T helper type 17/regulatory T cell paradigm in pregnancy. Immunology 2016; 148: 13–21.
11. Tesniere A, Panaretakis T, Kepp O, et al. Molecular characteristics of immunogenic cancer cell death. Cell Death Differ 2008; 15: 3–12.
12. Zitvogel L, Galluzzi L, Smyth MJ, Kroemer G. Mechanism of action of conventional and targeted anticancer therapies: Reinstating immunosurveillance. Immunity 2013; 39: 74–88.
13. Kroemer G, Galluzzi L, Kepp O, Zitvogel L. Immunogenic cell death in cancer therapy. Annu Rev Immunol 2013; 31: 51–72.
14. Garg AD, Dudek AM, Agostinis P. Cancer immunogenicity, danger signals, and DAMPs: What, when, and how? BioFactors 2013; 39: 355–367.
15. Garg AD, Martin S, Golab J, Agostinis P. Danger signalling during cancer cell death: Origins, plasticity and regulation. Cell Death Differ 2014; 21: 26–38.
16. Huang Y, Yin H, Han J, et al. Extracellular hmgb1 functions as an innate immune-mediator implicated in murine cardiac allograft acute rejection. Am J Transplant 2007; 7: 799–808.
17. Duan L, Wang CY, Chen J, et al. High-mobility group box 1 promotes early acute allograft rejection by enhancing IL-6-dependent Th17 alloreactive response. Lab Invest 2011; 91: 43–53.
18. Xia Q, Duan L, Shi L, Zheng F, Gong F, Fang M. High-mobility group box 1 accelerates early acute allograft rejection via enhancing IL-17 + γδ T-cell response. Transpl Int 2014; 27: 399–407.
19. Messmer D, Yang H, Telusma G, et al. High mobility group box protein 1: An endogenous signal for dendritic cell maturation and Th1 polarization. J Immunol 2004; 173: 307–313.
20. Yang D, Chen Q, Yang H, Tracey KJ, Bustin M, Oppenheim JJ. High mobility group box-1 protein induces the migration and activation of human dendritic cells and acts as an alarmin. J Leukoc Biol 2007; 81: 59–66.
21. Zhu XM, Yao YM, Liang HP, et al. The effect of high mobility group box-1 protein on splenic dendritic cell maturation in rats. J Interferon Cytokine Res 2009; 29: 677–686.
22. Zou H, Yang Y, Gao M, et al. HMGB1 is involved in chronic rejection of cardiac allograft via promoting inflammatory-like mDCs. Am J Transplant 2014; 14: 1765–1177.
23. Ledderose C, Bao Y, Zhang J, Junger WG. Novel method for real-time monitoring of ATP release reveals multiple phases of autocrine purinergic signalling during immune cell activation. Acta Physiol (Oxf) 2015; 213: 334–345.
24. Idzko M, Ferrari D, Eltzschig HK. Nucleotide signalling during inflammation. Nature 2014; 509: 310–317.
25. Vergani A, Tezza S, Fotino C, et al. The purinergic system in allotransplantation. Am J Transplant 2014; 14: 507–514.
26. Vergani A, Tezza S, D'Addio F, et al. Long-term heart transplant survival by targeting the ionotropic purinergic receptor P2X7. Circulation 2013; 127: 463–475.
27. Vergani A, Fotino C, D'Addio F, et al. Effect of the purinergic inhibitor oxidized ATP in a model of islet allograft rejection. Diabetes 2013; 62: 1665–1675.
28. Wilhelm K, Ganesan J, Muller T, et al. Graft-versus-host disease is enhanced by extracellular ATP activating P2X7R. Nat Med 2010; 16: 1434–1438.
29. Apostolova P, Zeiser R. The role of danger signals and ectonucleotidases in acute graft-versus-host disease. Hum Immunol. 2016. [Epub ahead of print].
30. Yoshida O, Dou L, Kimura S, et al. CD39 deficiency in murine liver allografts promotes inflammatory injury and immune-mediated rejection. Transpl Immunol 2015; 32: 76–83.
31. Suarez-Alvarez B, Lopez-Vazquez A, Baltar JM, Ortega F, Lopez-Larrea C. Potential role of NKG2D and its ligands in organ transplantation, new target for immunointervention. Am J Transplant 2009; 9: 251–257.
32. van der Touw W, Bromberg JS. Natural killer cells and the immune response in solid organ transplantation. Am J Transplant 2010; 10: 1354–1358.
33. Benichou G, Yamada Y, Aoyama A, Madsen JC. Natural killer cells in rejection and tolerance of solid organ allografts. Curr Opin Organ Transplant 2011; 16: 47–53.
34. Feng L, Ke N, Ye Z, et al. Expression of NKG2D and its ligand in mouse heart allografts may have a role in acute rejection. Transplant Proc 2009; 41: 4332–4339.
35. Hankey KG, Drachenberg CB, Papadimitriou JC, et al. MIC expression in renal and pancreatic allografts. Transplantation 2002; 73: 304–306.
36. Quiroga I, Salio M, Koo DD, et al. Expression of MHC class I-related Chain B (MICB) molecules on renal transplant biopsies. Transplantation 2006; 81: 1196–1203.
37. Suarez-Alvarez B, Alonso-Arias R, Bravo-Mendoza C, et al. Identification of epitopes and immunodominant regions on the MICA protein defined by alloantibodies from kidney transplant patients. Transplantation 2009; 88: S68–S77.
38. Zhang M, Carroll MC. Natural IgM-mediated innate autoimmunity: A new target for early intervention of ischemia-reperfusion injury. Expert Opin Biol Ther 2007; 7: 1575–1582.
39. Atkinson C, Qiao F, Yang X, et al. Targeting pathogenic postischemic self-recognition by natural IgM to protect against posttransplantation cardiac reperfusion injury. Circulation 2015; 131: 1171–1180.
40. Farrar CA, Sacks SH. Mechanisms of rejection: Role of complement. Curr Opin Organ Transplant 2014; 19: 8–13.
41. Sheen JH, Heeger PS. Effects of complement activation on allograft injury. Curr Opin Organ Transplant 2015; 20: 468–475.
42. Zhou W, Farrar CA, Abe K, et al. Predominant role for C5b-9 in renal ischemia/reperfusion injury. J Clin Invest 2000; 105: 1363–1371.
43. Peng Q, Li K, Smyth LA, et al. C3a and C5a promote renal ischemia-reperfusion injury. J Am Soc Nephrol 2012; 23: 1474–1485.
44. Zhou W. The new face of anaphylatoxins in immune regulation. Immunobiology 2012; 217: 225–234.
45. Błogowski W, Dołęgowska B, Sałata D, Budkowska M, Domański L, Starzyńska T. Clinical analysis of perioperative complement activity during ischemia/reperfusion injury following renal transplantation. Clin J Am Soc Nephrol 2012; 7: 1843–1851.
46. Damman J, Seelen MA, Moers C, et al. Systemic complement activation in deceased donors is associated with acute rejection after renal transplantation in the recipient. Transplantation 2011; 92: 163–169.
47. van Werkhoven MB, Damman J, van Dijk MC, et al. Complement mediated renal inflammation induced by donor brain death: Role of renal C5a-C5aR interaction. Am J Transplant 2013; 13: 875–882.
48. Mosbah IB, Zaouali MA, Martel C, et al. IGL-1 solution reduces endoplasmic reticulum stress and apoptosis in rat liver transplantation. Cell Death Dis 2012; 3: e279.
49. Emadali A, Nguyên DT, Rochon C, Tzimas GN, Metrakos PP, Chevet E. Distinct endoplasmic reticulum stress responses are triggered during human liver transplantation. J Pathol 2005; 207: 111–118.
50. Anderson CD, Upadhya G, Conzen KD, et al. Endoplasmic reticulum stress is a mediator of posttransplant injury in severely steatotic liver allografts. Liver Transpl 2011; 17: 189–200.
51. Thomas L. On immunosurveillance in human cancer. Yale J Biol Med 1982; 55: 329–333.
52. Garg A, Galluzzi L, Apetoh L, et al. Molecular and translational classifications of DAMPs in immunogenic cell death. Front Immunol 2015; 6: 588.
53. Garg AD, Dudek-Peric AM, Romano E, Agostinis P. Immunogenic cell death. Int J Dev Biol 2015; 59: 131–140.
54. Garg AD, Krysko DV, Vandenabeele P, Agostinis P. The emergence of phox-ER stress induced immunogenic apoptosis. Oncoimmunology 2012; 1: 786–788.
55. Pfirschke C, Engblom C, Rickelt S, et al. Immunogenic chemotherapy sensitizes tumors to checkpoint blockade therapy. Immunity 2016; 44: 1–12.
56. Mittal D, Gubin MM, Schreiber RD, Smyth MJ. New insights into cancer immunoediting and its three component phases-elimination, equilibrium and escape. Curr Opin Immunol 2014; 27: 16–25.
57. Whiteside TL. Induced regulatory T cells in inhibitory microenvironments created by cancer. Expert Opin Biol Ther 2014; 14: 1411–1425.
58. Kepp O, Senovilla L, Kroemer G. Immunogenic cell death inducers as anticancer agents. Oncotarget 2014; 5: 5190–5191.
59. Kepp O, Senovilla L, Vitale I, et al. Consensus guidelines for the detection of immunogenic cell death. Oncoimmunology 2014; 3: e955691.
60. Land WG. Emerging role of innate immunity in organ transplantation, part II: Potential of damage-associated molecular patterns to generate immunostimulatory dendritic cells. Transplant Rev (Orlando) 2012; 26: 73–87.
61. Kalogeris T, Baines CP, Krenz M, Korthuis RJ. Cell biology of ischemia/reperfusion injury. Int Rev Cell Mol Biol 2012; 298: 229–317.
62. Kuznetsov G, Bush KT, Zhang PL, Nigam SK. Perturbations in maturation of secretory proteins and their association with endoplasmic reticulum chaperones in a cell culture model for epithelial ischemia. Proc Natl Acad Sci USA 1996; 93: 8584–8589.
63. Toth A, Nickson P, Mandl A, Bannister ML, Toth K, Erhardt P. Endoplasmic reticulum stress as a novel therapeutic target in heart diseases. Cardiovasc Hematol Disord Drug Targets 2007; 7: 205–218.
64. Wang Y, Tian J, Qiao X, et al. Intermedin protects against renal ischemia-reperfusion injury by inhibiting endoplasmic reticulum stress. BMC Nephrol 2015; 16: 169.
65. Thapalia BA, Zhou Z, Lin X. Autophagy, a process within reperfusion injury: An update. Int J Clin Exp Pathol 2014; 7: 8322–8341.
66. Li L, Tan J, Miao Y, Lei P, Zhang Q. ROS and autophagy: Interactions and molecular regulatory mechanisms. Cell Mol Neurobiol 2015; 35: 615–621.
67. Decuypere JP, Ceulemans LJ, Agostinis P, et al. Autophagy and the kidney: Implications for ischemia-reperfusion injury and therapy. Am J Kidney Dis 2015; 66: 699–709.
68. McDonald B, Pittman K, Menezes GB, et al. Intravascular danger signals guide neutrophils to sites of sterile inflammation. Science 2010; 330: 362–366.
69. Whelan RS, Kaplinskiy V, Kitsis RN. Cell death in the pathogenesis of heart disease: Mechanisms and significance. Annu Rev Physiol 2010; 72: 19–44.
70. Schröder M, Kaufman RJ. The mammalian unfolded protein response. Annu Rev Biochem 2005; 74: 739–789.
71. Ron D, Walter P. Signal integration in the endoplasmic reticulum unfolded protein response. Nat Rev Mol Cell Biol 2007; 8: 519–529.
72. Hiramatsu N, Chiang WC, Kurt TD, Sigurdson CJ, Lin JH. Multiple mechanisms of unfolded protein response-induced cell death. Am J Pathol 2015; 185: 1800–1808.
73. Garg AD, Agostinis P. ER stress, autophagy and immunogenic cell death in photodynamic therapy-induced anti-cancer immune responses. Photochem Photobiol Sci 2014; 13: 474–487.
74. van Vliet AR, Martin S, Garg AD, Agostinis P. The PERKs of damage-associated molecular patterns mediating cancer immunogenicity: From sensor to the plasma membrane and beyond. Semin Cancer Biol 2015; 33: 74–85.
75. Kepp O, Menger L, Vacchelli E, et al. Crosstalk between ER stress and immunogenic cell death. Cytokine Growth Factor Rev 2013; 24: 311–318.
76. Kepp O, Semeraro M, Bravo-San Pedro JM, et al. eIF2α phosphorylation as a biomarker of immunogenic cell death. Semin Cancer Biol 2015; 33: 86–92.
77. Koks CA, Garg AD, Ehrhardt M, et al. Newcastle disease virotherapy induces long-term survival and tumor-specific immune memory in orthotopic glioma through the induction of immunogenic cell death. Int J Cancer 2015; 136: E313–E325.
78. Garg AD, Krysko DV, Verfaillie T, et al. A novel pathway combining calreticulin exposure and ATP secretion in immunogenic cancer cell death. EMBO J 2012; 31: 1062–1079.
79. Garg AD, Dudek AM, Ferreira GB, et al. ROS-induced autophagy in cancer cells assists in evasion from determinants of immunogenic cell death. Autophagy 2013; 9: 1292–1307.
80. Wiersma VR, Michalak M, Abdullah TM, Bremer E, Eggleton P. Mechanisms of translocation of ER chaperones to the cell surface and immunomodulatory roles in cancer and autoimmunity. Front Oncol 2015; 5: 7.
81. Panaretakis T, Joza N, Modjtahedi N, et al. The co-translocation of ERp57 and calreticulin determines the immunogenicity of cell death. Cell Death Differ 2008; 15: 1499–1509.
82. Panaretakis T, Kepp O, Brockmeier U, et al. Mechanisms of pre-apoptotic calreticulin exposure in immunogenic cell death. EMBO J 2009; 28: 578–590.
83. Dudek-Perić AM, Ferreira GB, Muchowicz A, et al. Antitumor immunity triggered by melphalan is potentiated by melanoma cell surface-associated calreticulin. Cancer Res 2015; 75: 1603–1614.
84. Gilardini Montani MS, D'Eliseo D, Cirone M, et al. Capsaicin-mediated apoptosis of human bladder cancer cells activates dendritic cells via CD91. Nutrition 2015; 31: 578–581.
85. Basu S, Binder RJ, Ramalingam T, Srivastava PK. CD91 is a common receptor for heat shock proteins gp96, hsp90, hsp70, and calreticulin. Immunity 2001; 14: 303–313.
86. Krysko DV, Vandenabeele P. Clearance of dead cells: Mechanisms, immune responses and implication in the development of diseases. Apoptosis 2010; 15: 995–997.
87. Weiss EM, Frey B, Rodel F, et al. Ex vivo- and in vivo-induced dead tumor cells as modulators of antitumor responses. Ann N Y Acad Sci 2010; 1209: 109–117.
88. Garg AD, Elsen S, Krysko DV, Vandenabeele P, de Witte P, Agostinis P. Resistance to anticancer vaccination effect is controlled by a cancer cell-autonomous phenotype that disrupts immunogenic phagocytic removal. Oncotarget 2015; 6: 26841–26860.
89. Martins I, Wang Y, Michaud M, et al. Molecular mechanisms of ATP secretion during immunogenic cell death. Cell Death Differ 2014; 21: 79–91.
90. Wang Y, Martins I, Ma Y, Kepp O, Galluzzi L, Kroemer G. Autophagy-dependent ATP release from dying cells via lysosomal exocytosis. Autophagy 2013; 9: 1624–1625.
91. Garg AD, Nowis D, Golab J, Vandenabeele P, Krysko DV, Agostinis P. Immunogenic cell death, DAMPs and anticancer therapeutics: An emerging amalgamation. Biochim Biophys Acta 2010; 1805: 53–71.
92. Chekeni FB, Elliott MR, Sandilos JK, et al. Pannexin 1 channels mediate ‘find-me’ signal release and membrane permeability during apoptosis. Nature 2010; 467: 863–867.
93. Lee WS, Yoo WH, Chae HJ. ER stress and autophagy. Curr Mol Med 2015; 15: 735–745.
94. Ayna G, Krysko DV, Kaczmarek A, Petrovski G, Vandenabeele P, Fésüs L. ATP release from dying autophagic cells and their phagocytosis are crucial for inflammasome activation in macrophages. PLoS ONE 2012; 7: e40069.
95. Liikanen I, Ahtiainen L, Hirvinen ML, et al. Oncolytic adenovirus with temozolomide induces autophagy and antitumor immune responses in cancer patients. Mol Ther 2013; 21: 1212–1223.
96. Martins I, Michaud M, Sukkurwala AQ, et al. Premortem autophagy determines the immunogenicity of chemotherapy-induced cancer cell death. Autophagy 2012; 8: 413–415.
97. Michaud M, Martins I, Sukkurwala AQ, et al. Autophagy-dependent anticancer immune responses induced by chemotherapeutic agents in mice. Science 2011; 334: 1573–1577.
98. Elliott MR, Chekeni FB, Trampont PC, et al. Nucleotides released by apoptotic cells act as a find-me signal to promote phagocytic clearance. Nature 2009; 461: 282–286.
99. Garg AD, Krysko DV, Vandenabeele P, Agostinis P. Extracellular ATP and P2X7 receptor exert context-specific immunogenic effects after immunogenic cancer cell death. Cell Death Dis 2016; 7: e2097.
100. Ma Y, Adjemian S, Yang H, et al. ATP-dependent recruitment, survival and differentiation of dendritic cell precursors in the tumor bed after anticancer chemotherapy. Oncoimmunology 2013; 2: e24568.
101. Ma Y, Adjemian S, Mattarollo SR, et al. Anticancer chemotherapy-induced intratumoral recruitment and differentiation of antigen-presenting cells. Immunity 2013; 38: 729–741.
102. Michaud M, Sukkurwala AQ, Martins I, Shen S, Zitvogel L, Kroemer G. Subversion of the chemotherapy-induced anticancer immune response by the ecto-ATPase CD39. Oncoimmunology 2012; 1: 393–395.
103. Aymeric L, Apetoh L, Ghiringhelli F, et al. Tumor cell death and ATP release prime dendritic cells and efficient anticancer immunity. Cancer Res 2010; 70: 855–858.
104. Ghiringhelli F, Apetoh L, Tesniere A, et al. Activation of the NLRP3 inflammasome in dendritic cells induces IL-1beta-dependent adaptive immunity against tumors. Nat Med 2009; 15: 1170–1178.
105. Di Virgilio F, Vuerich M. Purinergic signaling in the immune system. Auton Neurosci 2015; 191: 117–123.
106. Apetoh L, Ghiringhelli F, Tesniere A, et al. Toll-like receptor 4- dependent contribution of the immune system to anticancer chemotherapy and radiotherapy. Nat Med 2007; 13: 1050–1059.
107. Thorburn J, Horita H, Redzic J, Hansen K, Frankel AE, Thorburn A. Autophagy regulates selective HMGB1 release in tumor cells that are destined to die. Cell Death Differ 2009; 16: 175–183.
108. Tang D, Kang R, Zeh HJ 3rd, Lotze MT. High-mobility group box 1, oxidative stress, and disease. Antioxid Redox Signal 2011; 14: 1315–1335.
109. Tsung A, Tohme S, Billiar TR. High-mobility group box-1 in sterile inflammation. J Intern Med 2014; 276: 425–443.
110. Kang R, Livesey KM, Zeh HJ 3rd, Lotze MT, Tang D. HMGB1 as an autophagy sensor in oxidative stress. Autophagy 2011; 7: 904–906.
111. Ladoire S, Hannani D, Vetizou M, et al. Cell-death-associated molecular patterns as determinants of cancer immunogenicity. Antioxid Redox Signal 2014; 20: 1098–1116.
112. Sistigu A, Yamazaki T, Vacchelli E, et al. Cancer cell-autonomous contribution of type I interferon signaling to the efficacy of chemotherapy. Nat Med 2014; 20: 1301–1309.
113. Zitvogel L, Galluzzi L, Kepp O, Smyth MJ, Kroemer G. Type I interferons in anticancer immunity. Nat Rev Immunol 2015; 15: 405–414.
114. Garg AD, Vandenberk L, Koks C, et al. Dendritic cell vaccines based on immunogenic cell death elicit danger signals and T cell-driven rejection of high-grade glioma. Sci Transl Med 2016; 8: 328ra27.
115. Kawai T, Akira S. The role of pattern-recognition receptors in innate immunity: Update on Toll-like receptors. Nat Immunol 2010; 11: 373–384.
116. Ranoa DR, Parekh AD, Pitroda SP, et al. Cancer therapies activate RIG-I-like receptor pathway through endogenous non-coding RNAs. Oncotarget 2016; 7: 26496–26515.
117. Korbelik M, Sun J, Cecic I. Photodynamic therapy-induced cell surface expression and release of heat shock proteins: Relevance for tumor response. Cancer Res 2005; 65: 1018–1026.
118. Garg AD, Nowis D, Golab J, Agostinis P. Photodynamic therapy: Illuminating the road from cell death towards anti-tumour immunity. Apoptosis 2010; 15: 1050–1071.
119. Suzuki S, Kulkarni AB. Extracellular heat shock protein HSP90 beta secreted by MG63 osteosarcoma cells inhibits activation of latent TGF-beta1. Biochem Biophys Res Commun 2010; 398: 525–531.
120. Cirone M, Di Renzo L, Lotti LV, et al. Primary effusion lymphoma cell death induced by bortezomib and AG 490 activates dendritic cells through CD91. PLoS ONE 2012; 7: e31732.
121. Zunino B, Rubio-Patino C, Villa E, et al. Hyperthermic intraperitoneal chemotherapy leads to an anticancer immune response via exposure of cell surface heat shock protein 90. Oncogene 2016; 35: 261–268.
122. Lin TJ, Lin HT, Chang WT, et al. Shikonin-enhanced cell immunogenicity of tumor vaccine is mediated by the differential effects of DAMP components. Mol Cancer 2015; 14: 174.
123. Woo SR, Fuertes MB, Corrales L, et al. STING-dependent cytosolic DNA sensing mediates innate immune recognition of immunogenic tumors. Immunity 2014; 41: 830–842.
124. Klarquist J, Hennies CM, Lehn MA, Reboulet RA, Feau S, Janssen EM. STING-mediated DNA sensing promotes antitumor and autoimmune responses to dying cells. J Immunol 2014; 193: 6124–6134.
125. Dudek AM, Martin S, Garg AD, Agostinis P. Immature, semi-mature, and fully mature dendritic cells: Toward a DC-cancer cells interface that augments anticancer immunity. Front Immunol 2013; 4: 438.
126. Tran Janco JM, Lamichhane P, Karyampudi L, Knutson KL. Tumor-infiltrating dendritic cells in cancer pathogenesis. J Immunol 2015; 194: 2985–2991.
127. Mattarollo SR, Loi S, Duret H, Ma Y, Zitvogel L, Smyth MJ. Pivotal role of innate and adaptive immunity in anthracycline chemotherapy of established tumors. Cancer Res 2011; 71: 4809–4820.
128. Ma Y, Aymeric L, Locher C, et al. Contribution of IL-17-producing gamma delta T cells to the efficacy of anticancer chemotherapy. J Exp Med 2011; 208: 491–503.
129. Gebremeskel S, Johnston B. Concepts and mechanisms underlying chemotherapy induced immunogenic cell death: Impact on clinical studies and considerations for combined therapies. Oncotarget 2015; 6: 41600–41619.
130. Zhou Z, Yu X, Zhang J, Tian Z, Zhang C. TLR7/8 agonists promote NK-DC cross-talk to enhance NK cell anti-tumor effects in hepatocellular carcinoma. Cancer Lett 2015; 369: 298–306.
131. Hsu WM, Hsieh FJ, Jeng YM, et al. Calreticulin expression in neuroblastoma—A novel independent prognostic factor. Ann Oncol 2005; 16: 314–321.
132. Vandenabeele P, Vandecasteele K, Bachert C, Krysko O, Krysko DV. Immunogenic apoptotic cell death and anticancer immunity. Adv Exp Med Biol 2016; 930: 133–149.
133. Zappasodi R, Pupa SM, Ghedini GC, et al. Improved clinical outcome in indolent B-cell lymphoma patients vaccinated with autologous tumor cells experiencing immunogenic death. Cancer Res 2010; 70: 9062–9072.
134. Wemeau M, Kepp O, Tesnière A, et al. Calreticulin exposure on malignant blasts predicts a cellular anticancer immune response in patients with acute myeloid leukemia. Cell Death Dis 2010; 1: e104.
135. Liu R, Gong J, Chen J, et al. Calreticulin as a potential diagnostic biomarker for lung cancer. Cancer Immunol Immunother 2012; 61: 855–864.
136. Chen JS, Hsu YM, Chen CC, Chen LL, Lee CC, Huang TS. Secreted heat shock protein 90alpha induces colorectal cancer cell invasion through CD91/LRP-1 and NF-kappaB-mediated integrin alphaV expression. J Biol Chem 2010; 285: 25458–25466.
137. Chen WS, Chen CC, Chen LL, Lee CC, Huang TS. Secreted heat shock protein 90α (HSP90α) induces nuclear factor-κB-mediated TCF12 protein expression to down-regulate E-cadherin and to enhance colorectal cancer cell migration and invasion. J Biol Chem 2013; 288: 9001–9010.
138. Fucikova J, Moserova I, Urbanova L, et al. Prognostic and predictive value of DAMPs and DAMP-associated processes in cancer. Front Immunol 2015; 6: 402.
139. Chen CN, Chang CC, Su TE, et al. Identification of calreticulin as a prognosis marker and angiogenic regulator in human gastric cancer. Ann Surg Oncol 2009; 16: 524–533.
140. Erić A, Juranić Z, Milovanović Z, et al. Effects of humoral immunity and calreticulin overexpression on postoperative course in breast cancer. Pathol Oncol Res 2009; 15: 89–90.
141. Chao MP, Jaiswal S, Weissman-Tsukamoto R, et al. Calreticulin is the dominant pro-phagocytic signal on multiple human cancers and is counterbalanced by CD47. Sci Transl Med 2010; 2: 63ra94.
142. Marcus A, Gowen BG, Thompson TW, et al. Recognition of tumors by the innate immune system and natural killer cells. Adv Immunol 2014; 122: 91–128.
143. Raulet DH, Gasser S, Gowen BG, Deng W, Jung H. Regulation of ligands for the NKG2D activating receptor. Annu Rev Immunol 2013; 31: 413–441.
144. van Beek JJ, Wimmers F, Hato SV, de Vries IJ, Sköld AE. Dendritic cell cross talk with innate and innate-like effector cells in antitumor immunity: Implications for DC vaccination. Crit Rev Immunol 2014; 34: 517–536.
145. Jackson SP, Bartek J. The DNA-damage response in human biology and disease. Nature 2009; 461: 1071–1078.
146. Ciccia A, Elledge SJ. The DNA damage response: Making it safe to play with knives. Mol Cell 2010; 40: 179–204.
147. Härtlova A, Erttmann SF, Raffi FA, et al. DNA damage primes the type I interferon system via the cytosolic DNA sensor STING to promote anti-microbial innate immunity. Immunity 2015; 42: 332–343.
148. Le Bert N, Lam AR, Ho SS, Shen YJ, Liu MM, Gasser S. STING-dependent cytosolic DNA sensor pathways regulate NKG2D ligand expression. Oncoimmunology 2014; 3: e29259.
149. Gasser S, Orsulic S, Brown EJ, Raulet DH. The DNA damage pathway regulates innate immune system ligands of the NKG2D receptor. Nature 2005; 436: 1186–1190.
150. Chen B, Wu Z, Xu J, Xu Y. Calreticulin binds to Fas ligand and inhibits neuronal cell apoptosis induced by ischemia-reperfusion injury. Biomed Res Int 2015; 2015: 895284.
151. Xia JG, Xu FF, Qu Y, Song DG, Shen H, Liu XH. Atorvastatin post-conditioning attenuates myocardial ischemia reperfusion injury via inhibiting endoplasmic reticulum stress-related apoptosis. Shock 2014; 42: 365–371.
152. Trautmann A. Extracellular ATP in the immune system: More than just a “danger signal”. Sci Signal 2009; 2: pe6.
153. Zhai Y, Shen XD, Gao F, et al. CXCL10 regulates liver innate immune response against ischemia and reperfusion injury. Hepatology 2008; 47: 207–214.
154. Freitas MC, Uchida Y, Lassman C, Danovitch GM, Busuttil RW, Kupiec-Weglinski JW. Type I interferon pathway mediates renal ischemia/reperfusion injury. Transplantation 2011; 92: 131–138.
155. Savage PA, Leventhal DS, Malchow S. Shaping the repertoire of tumor-infiltrating effector and regulatory T cells. Immunol Rev 2014; 259: 245–258.
156. Katoh H, Watanabe M. Myeloid-derived suppressor cells and therapeutic strategies in cancer. Mediators Inflamm 2015; 2015: 159269.
157. Matzinger P, Kamala T. Tissue-based class control: The other side of tolerance. Nat Rev Immunol 2011; 11: 221–230.
158. Verginis P, McLaughlin KA, Wucherpfennig KW, von Boehmer H, Apostolou I. Induction of antigen-specific regulatory T cells in wild-type mice: Visualization and targets of suppression. Proc Natl Acad Sci USA 2008; 105: 3479–3484.
159. Linkermann A. Nonapoptotic cell death in acute kidney injury and transplantation. Kidney Int 2016; 89: 46–57.